Raises FY23 revenue view to $58.6B-$59.6B from $57.7B-$58.9B, consensus $53.18B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Notable companies reporting before tomorrow’s open
- MRK Earnings this Week: How Will it Perform?
- Merck reports Phase 3 KEYNOTE-756 trial met one of dual primary endpoints
- Ligand says Merck reports V116 met key endpoints in two Phase 3 trials
- Merck: V1166 met key immunogenicity, safety endpoints in two Phase 3 trials